Monitoring target specific anticoagulants
New, target specific, oral anticoagulants have been shown to be safe and effective in prevention and treatment of thromboembolism without laboratory monitoring. However, clinical use of the drugs dabigatran, rivaroxaban, and apixaban requires laboratory measurement of their anticoagulant effect in specific clinical situations. This paper reviews the data available on use of screening and specialized testing to measure the anticoagulant effect and drug levels in patients prescribed these medications. Their effect on other coagulation assays is also reviewed.
KeywordsDabigatran Rivaroxaban Apixaban Coagulation testing Monitoring
- 15.Pengo V, Crippa L, Falanga A et al (2011) Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 106:868–876PubMedCrossRefGoogle Scholar
- 20.Harenberg J, Kraemer S, Du S, Giese C, Kraemer R (2012) Point of care method for the determination of dabigatran in urine samples from patients on treatment. American Society of Hematology Meeting Abstract #2270, San DiegoGoogle Scholar